In 2017 and 2019 the US FDA approved Enasidenib AG-221 for IDH2 mutated AML in adult relapsed/refractory (r/r) patients, and Ivosidenib AG120 in patients with IDH1 mutations over 75 years of age or not eligible for standard chemotherapy treatment. The gene discussed is IDH2; the disease is acute myeloid leukemia.